SciClone Pays $6 Million for China Rights to Theravance's Antibiotic

SciClone Pharma in-licensed greater China rights to Vibativ® (telavancin), an antibiotic developed by Theravance Biopharma in exchange for a package of $6 million in upfront and milestone payments. Both companies are based in the US, though SciClone's marketing operations are focused on China. SciClone will initially seek CFDA approval of Vibativ for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. More details.... Stock Symbols: (NSDQ: SCLN) (NSDQ: TBPH) Share this with colleagues: // //